Uses of medication: Aliqopa (Copanlisib) is used in order to treat adult patients with relapsed follicular lymphoma (FL) who have received at least 2-prior systemic therapies.

Dosage: The recommended aliqopa 60 mg dose should be administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3-weeks on and 1-week off). Treatment with aliqopa should be continued until the disease progression or not acceptable toxicity.

Treatment Reactions: The most commonly reported aliqopa side effects include:

  • Hyperglycemia
  • Diarrhea
  • Hypertension
  • Leukopenia
  • Neutropenia
  • Nausea
  • Lower respiratory tract infections
  • Thrombocytopenia
  • Decreased general strength and energy

Warnings and Precautions:

  • Diabetes mellitus patients should only be treated with aliqopa 60 mg after adequate glucose control and should be monitored closely.
  • Pre- and post-infusion of copanlisib, patients should be monitored for BP.
  • While on treatment with copanlisib 60 mg patients should be monitored for blood counts at least weekly basis.
  • Do not administer copanlisib during pregnancy, as this medication can be responsible for causing fetal harm if administered to a pregnant woman.
  • Lactating women should not breastfeed during treatment with copanlisib 60 mg and for at least 30 days following the final dose.
  • Patients with aliqopa should be monitored for signs and symptoms of infection. Withhold the treatment for Grade-3 and higher infections until the resolution.